Retension Pharmaceuticals, Inc. (NASDAQ:RTSN – Get Free Report) Director Franklin Berger purchased 10,000 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were bought at an average price of $12.00 per share, with a total value of $120,000.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $120,000. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Retension Pharmaceuticals Stock Performance
Shares of Retension Pharmaceuticals stock opened at $12.21 on Friday. Retension Pharmaceuticals, Inc. has a 52 week low of $9.66 and a 52 week high of $12.86.
About Retension Pharmaceuticals
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
Further Reading
- Five stocks we like better than Retension Pharmaceuticals
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
